Vistagen Therapeutics, Inc. VTGN
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +3.1% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 132 cents this year.
The 19-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | ◌ | 0.0 | 0.0 | 0.0 | ◌ | ◌ | 0.0 | 0.0 | 0.0 | ◌ | ◌ | ◌ |
| Operating income $B | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ |
| EBITDA $B | −0.1 | −0.1 | −0.0 | −0.1 | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ | ◌ |
| Net income $B | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | ◌ | ◌ | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| EPS, diluted $ | −1.83 | −1.67 | −1.52 | −8.51 | ◌ | −0.49 | −0.50 | −0.90 | −1.12 | −1.54 | −29.08 | −10.61 | −3.81 | −1.27 | −0.83 | −1.81 | ◌ | ◌ | ◌ |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −131.6 | −55.7 | −46.5 | −154.3 | −61.0 | — | — | −351.5 | −380.9 | — | — | — | — | — | — | — | — | — | — |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 18 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.